Répertoire du corps professoral

A Phase II, Multicentre, Open-label,[...]Efficacy and Safety of Datopotamab Deruxtecan(Dato-DXd) as Monotherapy[...]with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours(TROPION-PanTumor03)(sub-study 6:Bladder)
Organisme(s) subventionnaire(s): AstraZeneca Canada inc.
Type de financement: Contrat
Établissement tête: Université Laval
Du 6 décembre 2023 au 25 décembre 2028

A Phase Ill Randomized, Open-Label,...Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative...Muscle Invasive Bladder Cancer (VOLGA)...
Organisme(s) subventionnaire(s): AstraZeneca
Type de financement: Contrat
Établissement tête: Université Laval
Du 23 août 2023 au 25 décembre 2029

Publications des 5 dernières années

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. The Lancet. Oncology, 2019/05. Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. DOI 10.1016/s1470-2045(19)30178-0

Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). Journal of cancer education : the official journal of the American Association for Cancer Education, 2019/02. Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Breau RH. DOI 10.1007/s13187-017-1259-7